News

Filter

Current filters:

Concert Pharmaceuticals

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Jazz Pharma and Concert ink deal on deuterium-modified sodium oxybate

27-02-2013

US drugmakers Jazz Pharmaceuticals (Nasdaq: JAZZ) and Concert Pharmaceuticals have entered into an exclusive…

BiotechnologyConcert PharmaceuticalsJazz PharmaceuticalsLicensingNeurologicalPharmaceuticalResearchsodium oxybateZyrem

Concert gets $4 million milestone in GlaxoSmithKline collaboration; progresses drug candidates

21-06-2011

US drug developer Concert Pharmaceuticals says that it has achieved a $4 million milestone in its strategic…

Anti-viralsConcert PharmaceuticalsDiabetesFinancialGlaxoSmithKlineLicensingNeurologicalPharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top